natgillin/translations-raw huggingface dataset:
This was considered acceptable since Revatio and Viagra have the same composition and are made in the same way by the same manufacturer.
To je bilo sprejemljivo, saj imata zdravili Revatio in Viagra enako sestavo in ju na enak način izdeluje isti izdelovalec.
This is a summary of the European public assessment report (EPAR) for Granpidam.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Granpidam.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Granpidam was considered to be comparable to Revatio.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Granpidam primerljivo z zdravilom Revatio.
This means that Granpidam is similar to a ‘reference medicine' already authorised in the European Union (EU) called Revatio.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Revatio.
Because Granpidam is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Granpidam generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
In adults, it is used in patients with class II (slight limitation of physical activity) or class III (marked limitation of physical activity) PAH.
Pri odraslih se uporablja pri bolnikih s PAH razreda II (blaga omejitev telesne aktivnosti) ali razreda III (izrazita omejitev telesne aktivnosti).
Granpidam is available as tablets (20 mg).
Zdravilo Granpidam je na voljo v obliki tablet (20 mg).
Because the effectiveness and safety of sildenafil in PAH is already well established, studies in people have been limited to tests to determine that it is bioequivalent to another authorised sildenafilcontaining tablet.
Ker sta učinkovitost in varnost sildenafila pri PAH že dobro raziskani, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je zdravilo biološko enakovredno drugi odobreni tableti, ki vsebuje sildenafil.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom dose would be 10 mg three times a day but Granpidam can only be used when a 20-mg dose is to be given.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom priporočeni odmerek 10 mg trikrat na dan, vendar se sme zdravilo Granpidam uporabljati le, kadar se dajejo odmerki po 20 mg. Za manjše odmerke je treba uporabiti druga zdravila, ki vsebujejo sildenafil.
In this case Granpidam was not compared with the reference product Revatio, but with Viagra.
V tem primeru zdravila Granpidam niso primerjali z referenčnim zdravilom Revatio, pač pa z zdravilom Viagra.
Other information about Granpidam
Druge informacije o zdravilu Granpidam
The active substance in Granpidam, sildenafil, belongs to a group of medicines called ‘phosphodiesterase-type-5 (PDE5) inhibitors', which means that it blocks the PDE5 enzyme.
Zdravilna učinkovina v zdravilu Granpidam, sildenafil, spada v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5), kar pomeni, da zavira encim PDE5.
In children weighing less than 20 kg the maximum recommended
Pri otrocih, ki tehtajo manj kot 20 kg, bi bil največji
Granpidam is a medicine used to treat adults and children from 1 year of age with pulmonary arterial hypertension (PAH, abnormally high blood pressure in the arteries in the lungs).
Zdravilo Granpidam se uporablja za zdravljenje odraslih in otrok, starejših od enega leta, s pljučno arterijsko hipertenzijo (PAH, nenormalno visok krvni tlak v pljučnih arterijah).
What are the benefits and risks of Granpidam?
Kakšne so koristi in tveganja, povezani z zdravilom Granpidam?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Granpidam have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo tega zdravila upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
When it is blocked, a substance called ‘cyclic guanine monophosphate' (cGMP) cannot be broken down, so that it remains in the vessels where it causes relaxation and widening of the blood vessels.
Kadar je zavrt, se snov, imenovana ciklični gvanozinmonofosfat (cGMP), ne more razgrajevati in ostaja v žilah, kjer povzroča sproščanje in razširitev krvnih žil.
The Committee recommended that Granpidam be approved for use in the EU.
Priporočil je, da se zdravilo Granpidam odobri za uporabo v EU.
For more information about treatment with Granpidam, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Granpidam preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Granpidam can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in the treatment of PAH.
Predpisovanje in izdaja zdravila Granpidam je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik z izkušnjami z zdravljenjem PAH.
In patients with PAH, sildenafil widens the blood vessels of the lungs, which lowers the blood pressure and improves symptoms.
Pri bolnikih s PAH sildenafil širi krvne žile v pljučih in tako znižuje krvni tlak in izboljšuje simptome.
In adults, Granpidam is taken at a dose of 20 mg three times a day.
Pri odraslih se zdravilo Granpidam jemlje v odmerku 20 mg trikrat na dan.
For practical information about using Granpidam, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Granpidam naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Why is Granpidam approved?
Zakaj je bilo zdravilo Granpidam odobreno?
What is Granpidam and what is it used for?
Kaj je zdravilo Granpidam in za kaj se uporablja?
Lower doses of Granpidam may be needed in patients taking some medicines that affect the way Granpidam is broken down in the body.
Pri bolnikih, ki jemljejo nekatera zdravila, ki vplivajo na presnovo zdravila Granpidam v telesu, so morda potrebni manjši odmerki.
Granpidam contains the active substance sildenafil.
Zdravilo Granpidam vsebuje zdravilno učinkovino sildenafil.
In children aged 1 to 17 years, the recommended dose is 20 mg three times a day in those over 20 kg. Higher doses should not be used.
Pri otrocih, starih od 1 do 17 let, ki tehtajo več kot 20 kg, je priporočeni odmerek 20 mg trikrat na dan.
PAH is a debilitating disease where there is severe constriction (narrowing) of the blood vessels of the lungs.
PAH je izčrpavajoča bolezen, pri kateri pride do hudega zoženja krvnih žil v pljučih.
How has Granpidam been studied?
Kako je bilo zdravilo Granpidam raziskano?
How is Granpidam used?
Kako se zdravilo Granpidam uporablja?
Therefore, the CHMP's view was that, as for Revatio, the benefit of Granpidam outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Revatio odtehtajo znana tveganja.
Date of first authorisation: 17 May 2000 Date of last renewal: 10 May 2010
Datum prve odobritve: 17. maj 2000 Datum zadnjega podaljšanja: 10. maj 2010
The relevance of these data for humans is unknown.
Pomen teh podatkov za ljudi ni znan.
• At the request of the European Medicines Agency:
• na zahtevo Evropske agencije za zdravila;
No teratogenic effects were observed.
Teratogenih učinkov niso opažali.
Special care should be taken in women with signs and symptoms of active allergic conditions.
Posebna previdnost je potrebna pri ženskah z znaki in simptomi aktivnih alergijskih stanj.
If you administer the injections yourself or have it done by your partner, follow the instructions below carefully.
Če si injekcije dajete sami ali vam jih daje vaš partner, se natančno držite spodnjih navodil.
Do not use this medicine after the expiry date which is stated on the carton and on the label after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na nalepki poleg oznake "EXP".
However, based on the small number of patients treated so far, an effect cannot be excluded.
Kljub temu pa na podlagi majhnega števila doslej zdravljenih bolnic ne moremo izključiti določenega vpliva telesne mase.
N.V. Organon, Kloosterstraat 6 Postbus 20
Organon Kloosterstraat 6 Postbus 20
In clinical studies, luteal phase support was given according to study centres' practice or according to the clinical protocol.
V kliničnih študijah so dajali podporo lutealne faze glede na prakso raziskovalnega centra ali glede na klinični protokol.
1, D-pClPhe
1, D-pCIPhe
The local reactions generally disappear within 4 hours after administration.
Lokalne reakcije so v splošnem izginile v 4 urah po aplikaciji.
Excretion occurs via faeces (approximately 75 %) and urine (approximately 22 %).
Zdravilo se izloča z blatom (približno 75 %) in urinom (približno 22 %).
5340 BH Oss, The Netherlands.
5340 BH Oss Nizozemska
It is not known whether ganirelix is excreted in breast milk.
Ni znano, ali se ganireliks izloča v materino mleko.
Gonadotrophins play an important role in human fertility and reproduction.
Gonadotropini igrajo pomembno vlogo v zvezi s plodnostjo in reprodukcijo pri ljudeh.
Your doctor will decide, depending on the severity, if additional monitoring is required during treatment.
Glede na jakost alergije se bo zdravnik odločil, ali bo med zdravljenjem potrebno dodatno spremljanje.
Follicles are small round sacs that contain the egg cells.
Folikli so majhne okrogle vrečke, ki vsebujejo jajčne celice.
The chance of having a side effect is described by the following categories:
Pogostnost neželenih učinkov je opisana z naslednjimi kategorijami:
The frequency of hypersensitivity reactions (very rare, < 1/10,000) has been deduced from post-marketing surveillance.
Pogostnost preobčutljivostnih reakcij (zelo redke, < 1/10.000) so ugotovili iz postmarketinških izkušenj.
The major circulating component in plasma is ganirelix.
Glavna komponenta, ki kroži v plazmi, je ganireliks.
The amino acids at positions 1, 2, 3, 6, 8 and 10 of the natural GnRH decapeptide have been substituted resulting in N-Ac-D-Nal(2)
Aminokisline na mestih 1, 2, 3, 6, 8 in 10 naravnega dekapeptida GnRH so zamenjane tako, da nastane N-Ac-D-Nal(2)
Ganirelix is also the main compound found in urine.
Ganireliks je tudi glavna spojina, ki se pojavi v urinu.
As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists.
Posledica tega je hitro, temeljito in reverzibilno zaviranje endogenih gonadotropinov brez začetne stimulacije, ki jo povzročajo agonisti GnRH.
If you have an active allergic condition, please tell your doctor.
Če imate aktivno alergijo, obvestite zdravnika.
There are no adequate data from the use of ganirelix in pregnant women.
Ni zadostnih podatkov o uporabi ganireliksa pri nosečnicah.
If you realise that you forgot a dose, administer it as soon as possible.
Če ugotovite, da ste pozabili posamezen odmerek, si ga injicirajte čim prej.
Start again with a new syringe.
Postopek ponovite z novo brizgo.
If you are more than 6 hours late (so the time between two injections is longer than 30 hours) administer the dose as soon as possible and contact your doctor for further advice.
Če ste zamudili več kot 6 ur (tako da je časovni razmik med dvema odmerkoma več kot 30 ur), si čim prej injicirajte odmerek in se posvetujte z zdravnikom.
The bioavailability of Orgalutran following subcutaneous administration is approximately 91 %.
Biološka uporabnost zdravila Orgalutran po subkutanem dajanju je približno 91 %.
The possibility of interactions with commonly used medicinal products, including histamine liberating medicinal products, cannot be excluded.
Možnosti za pojav interakcij s pogosto uporabljenimi zdravili, vključno s tistimi zdravili, ki sproščajo histamin, ni mogoče izključiti.
Serum hormone levels returned to pre-treatment values within two days after the last injection.
Serumske koncentracije hormonov so se vrnile na vrednosti pred zdravljenjem v dveh dneh po zadnji injekciji.
Based on your ovarian response, your doctor may decide to start on another day.
Na podlagi odziva vaših jajčnikov se lahko zdravnik odloči tudi, da bo z zdravljenjem začel kateri drug dan.
If you have an allergic reaction, stop taking Orgalutran and seek immediate medical assistance.
Če se pojavi alergijska reakcija, prenehajte jemati zdravilo Orgalutran in takoj poiščite zdravniško pomoč.
Checking the correct needle position
Preverjanje pravilne lege igle
]-GnRH with a molecular weight of 1570.4.
-GnRH, z molekulsko maso 1570,4.
For posology and method of administration, see section 4.2.
Za odmerjanje in način uporabe glejte poglavje 4.2.
Do not mix Orgalutran with any other medicines.
Zdravila Orgalutran ne smete mešati z drugimi zdravili.
The patient or her partner may perform the injections of Orgalutran themselves, provided that they are adequately instructed and have access to expert advice.
Bolnica ali njen partner lahko tudi sama injicirata zdravilo Orgalutran, pod pogojem, da sta bila ustrezno poučena o tem in se imata možnost posvetovati s strokovnjakom.
Similar comparative studies with corifollitropin alfa using either a GnRH antagonist or long agonist protocol have not been performed.
Podobne primerjalne študije s korifolitropinom alfa in uporabo bodisi antagonista GnRH ali protokola z dolgo delujočim agonistom niso bile izvedene.
Children and adolescents There is no relevant use of Orgalutran in children or adolescents.
Otroci in mladostniki Zdravilo Orgalutran ni primerno za uporabo pri otrocih ali mladostnikih.
The solution is ready for use and intended for subcutaneous administration.
Raztopina je pripravljena za uporabo in namenjena za subkutano uporabo.
Cases of allergic reactions have been reported, as early as with the first dose.
O primerih alergijskih reakcij so poročali že pri prvem odmerku.
The elimination half-life (t½) is approximately 13 hours and clearance is approximately 2.4 L/h.
Razpolovni čas izločanja (t1/2) je približno 13 ur in očistek približno 2,4 l/h.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
In case of overdose, Orgalutran treatment should be (temporarily) discontinued.
V primeru prevelikega odmerjanja je treba zdravljenje z zdravilom Orgalutran (začasno) prekiniti.
Please refer to the Package Leaflet of the gonadotrophin-containing medicine prescribed for you.
Preberite navodilo za uporabo za gonadotropin vsebujoče zdravilo, ki so vam ga predpisali.
Following administration of multiple doses of 0.25 mg Orgalutran to female volunteers serum LH, FSH and E2 concentrations were maximally decreased by 74 %, 32 % and 25 % at 4, 16 and 16 hours after injection, respectively.
Po večkratnih 0,25 mg odmerkih zdravila Orgalutran prostovoljkam so se serumske koncentracije LH, FSH in E2 zmanjšale za največ 74 %, 32 % in 25 % v 4, 16 in 16 urah po injiciranju.
Very rare: may affect up to 1 in 10,000 women Allergic reactions have been observed, as early as with the first dose.
Zelo redki: pojavijo se lahko pri največ 1 od 10.000 bolnic - alergijske reakcije so opažali že pri prvem odmerku.
The adverse reactions are classified according to MedDRA system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100).
Neželeni učinki so razvrščeni v skladu s klasifikacijo MedDRA po organskih sistemih in po pogostnosti; zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100).
In women, FSH is needed for the growth and development of follicles in the ovaries.
FSH je potreben za rast in razvoj foliklov v jajčnikih pri ženskah.
The local reaction normally disappears within 4 hours of administration.
Lokalna reakcija običajno izgine v 4 urah po injiciranju.
Clinical studies with subcutaneous administration of Orgalutran at single doses up to 12 mg did not show systemic adverse reactions.
Klinične študije z zdravilom Orgalutran pri enkratnem subkutanem odmerku do 12 mg niso pokazale sistemskih neželenih učinkov.
Do not use Orgalutran during pregnancy and breast-feeding.
Zdravila Orgalutran ne smete uporabljati med nosečnostjo in dojenjem.
The need for luteal phase support in cycles using Orgalutran has not been studied.
Potrebe po podpori lutealne faze v ciklusu z uporabo zdravila Orgalutran niso raziskovali.
The safety and efficacy of Orgalutran have not been established in women weighing less than 50 kg or more than 90 kg (see also section 5.1 and 5.2).
Varnost in učinkovitost zdravila Orgalutran nista bili dokazani pri ženskah s telesno maso manjšo od 50 kg ali večjo od 90 kg (glejte tudi poglavji 5.1 in 5.2).
Pharmacokinetic parameters after multiple subcutaneous dosing of Orgalutran (once daily injection) were similar to those after a single subcutaneous dose.
Farmakokinetični parametri po večkratnih subkutanih odmerkih zdravila Orgalutran (injiciranje enkrat dnevno) so bili podobni parametrom po enkratnem subkutanem odmerku.
No data on acute toxicity of Orgalutran in humans are available.
Podatkov o akutni toksičnosti zdravila Orgalutran pri ljudeh ni na voljo.
Gently draw back the plunger to check if the needle is positioned correctly.
Previdno potegnite bat nazaj, da preverite, ali je igla v pravilni legi.
Orgalutran has shown to be safe and effective in women undergoing multiple treatment cycles.
Zdravilo Orgalutran se je izkazalo za varno in učinkovito zdravilo pri ženskah zdravljenih z večimi ciklusi zdravljenj.
Once the needle has been correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin tissues are not damaged.
Ko je igla enkrat pravilno vbodena, počasi in enakomerno potisnite bat, da bo raztopina pravilno injicirana in ne boste poškodovali kožnega tkiva.
The metabolites are small peptide fragments formed by enzymatic hydrolysis of ganirelix at restricted sites.
Presnovki so majhni peptidni fragmenti, ki nastanejo pri encimski hidrolizi ganireliksa na omejenih predelih.
During Orgalutran treatment the average incidence of LH rises (> 10 IU/L) with concomitant progesterone rise (> 1 ng/mL) was 0.3 - 1.2 % compared to 0.8 % during GnRH agonist treatment.
Med zdravljenjem z zdravilom Orgalutran je bila povprečna incidenca zvišanja vrednosti LH (> 10 i.e./l) s sočasnim zvišanjem vrednosti progesterona (> 1 ng/ml) 0,3 - 1,2 % v primerjavi z 0,8 % med zdravljenjem z agonistom GnRH.
What Orgalutran is and what it is used for
Kaj je zdravilo Orgalutran in za kaj ga uporabljamo
Swab the injection site with a disinfectant (for example alcohol) to remove any surface bacteria.
Mesto injiciranja očistite z razkužilom (na primer z alkoholom), da odstranite bakterije na površini kože.
In clinical studies, one hour after injection, the incidence of at least once a moderate or severe local skin reaction per treatment cycle, as reported by patients, was 12 % in Orgalutran treated patients and 25 % in patients treated subcutaneously with a GnRH agonist.
V kliničnih študijah je bila eno uro po injiciranju pogostnost najmanj ene zmerne ali hude lokalne kožne reakcije na ciklus zdravljenja, o katerih so poročale bolnice, 12 % pri bolnicah zdravljenih z zdravilom Orgalutran in 25 % pri bolnicah zdravljenih subkutano z agonistom GnRH.
What Orgalutran looks like and contents of the pack Orgalutran is a clear and colourless aqueous solution for injection.
Izgled zdravila Orgalutran in vsebina pakiranja Zdravilo Orgalutran je bistra in brezbarvna vodna raztopina za injiciranje.
Do not use this syringe and dispose of it properly.
Brizge ne smete več uporabiti - pravilno jo zavrzite.
Use the pre-filled syringe only once.
Napolnjeno injekcijsko brizgo smete uporabiti le enkrat.
• Difficulty breathing (dyspnoea)
• oteženo dihanje (dispneja)
In case of a high ovarian response, either as a result of a high exposure to gonadotrophins in the early follicular phase or as a result of high ovarian responsiveness, premature LH rises may occur earlier than day 6 of stimulation.
V primeru močnega odziva jajčnikov, bodisi zaradi izpostavljenosti veliki koncentraciji gonadotropinov v zgodnji folikularni fazi ali kot posledica velike odzivnosti samih jajčnikov, lahko pride do prezgodnjega zvišanja koncentracije LH prej kot na 6. dan stimulacije.
Women weighing less than 50 kg or more than 90 kg
Ženske s telesno maso manj kot 50 kg ali več kot 90 kg
• Swelling of face, lips, tongue, and/or throat that may cause difficulty in breathing and/or swallowing (angioedema and/or anaphylaxis)
• otekanje obraza, ustnic, jezika in/ali grla, kar lahko povzroči težave pri dihanju in/ali požiranju (angioedem in/ali anafilaksija)
In animals, exposure to ganirelix at the time of implantation resulted in litter resorption (see section 5.3).
Pri živalih so ugotovili, da je izpostavljenost ganireliksu v času implantacije povzročila resorpcijo zarodkov (glejte poglavje 5.3).
This syndrome is related to the stimulation procedure with gonadotrophins.
Ta sindrom je povezan s postopkom spodbujanja jajčnikov z gonadotropini.
Pharmacokinetic analysis indicates an inverse relationship between body weight and serum concentrations of Orgalutran.
Analiza farmakokinetike kaže na obratno sorazmerje med telesno maso in serumskimi koncentracijami zdravila Orgalutran.
Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
OHSS should be treated symptomatically, e.g. with rest, intravenous infusion of electrolyte solutions or colloids and heparin.
OHSS je treba zdraviti simptomatsko, to je s počitkom, intravensko infuzijo elektrolitov ali s koloidi in heparinom.
In patients undergoing controlled ovarian stimulation the median duration of Orgalutran treatment was 5 days.
Pri bolnicah, ki so bile vključene v postopek nadzorovane stimulacije jajčnikov, je bila mediana vrednost dolžine zdravljenja z zdravilom Orgalutran 5 dni.
The start of Orgalutran may be delayed in absence of follicular growth, although clinical experience is based on starting Orgalutran on day 5 or day 6 of stimulation.
Začetek zdravljenja z zdravilom Orgalutran se lahko zakasni, če ni rasti folikla, vendar klinične izkušnje temeljijo na začetku uporabe zdravila Orgalutran na 5. ali 6. dan stimulacije.
Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, anti-gonadotrophin-releasing hormones, ATC code: H01CC01.
Farmakoterapevtska skupina: Hipofizni in hipotalamični hormoni ter sorodne učinkovine, antagonisti gonadotropin sproščajočih hormonov, oznaka ATC: H01CC01.
Use only syringes with clear, particle-free solutions and from undamaged containers.
Uporabite samo brizge z bistro raztopino, brez vidnih delcev in iz nepoškodovanih vsebnikov.
In clinical studies investigating more than 1,000 newborns it has been demonstrated that the incidence of congenital malformations in children born after COH treatment using Orgalutran is comparable with that reported after COH treatment using a GnRH agonist.
Klinične študije, v katerih so preiskovali več kot 1.000 novorojenčkov, so pokazale, da je pogostnost kongenitalnih malformacij pri otrocih, ki so bili rojeni po zdravljenju s COH z uporabo zdravila Orgalutran primerljiva s tistimi, o katerih so poročali po zdravljenju s COH z uporabo GnRH agonistov.
In the absence of clinical experience, Orgalutran treatment is not advised in women with severe allergic conditions.
Zaradi pomanjkanja kliničnih izkušenj uporaba zdravila Orgalutran ni priporočljiva za ženske s hudimi alergijami.
If you use more Orgalutran than you should Contact your doctor.
Če ste uporabili večji odmerek zdravila Orgalutran, kot bi smeli Obvestite zdravnika.